News
Vitafoods Europe organization selected Bioibericas new ingredient Mobilee® to take an important part in the event.
The results show that this drug combination significantly improves a patient’s pain, disability, rigidity, inflammation, joint effusion, and overall quality of life.There was a roughly 50% improvement in pain and functional disability. Any improvement in excess of 20% is considered clinically significant.
The results show that this drug combination significantly improves a patients pain, disability, rigidity, inflammation, joint effusion, and overall quality of life.There was a roughly 50% improvement in pain and functional disability. Any improvement in excess of 20% is considered clinically significant.
Bioiberica whises to inform its customers that its heparin sodium is fully compliant with the new requirements established by the Heparin Sodium USP monograph revision that is effective in USP 37 NF32, on May 1st, 2014.
During the 9th ISFFEI, held at Thailands capital on May 11-17, 2015, Bioibericas Plant Physiology Division presented the results of a new Cera Trap® trial.